Amino acid infusion during anesthesia attenuates the surgery induced decline in IGF-1 and diminishes the "diabetes of injury"

1743-7075-4-2 1743-7075 Research Amino acid infusion during anesthesia attenuates the surgery induced decline in IGF-1 and diminishes the "diabetes of injury" Wallin KEB Mats mats.wallin@ki.se Selldén Eva eva.sellden@karolinska.se Eksborg Staffan staffan.eksborg@karolinska.se Brismar Kerstin kerstin.brismar@ki.se

Department of Anesthesiology and Intensive Care, Karolinska University Hospital, Stockholm, Sweden

Department of Woman and Child Health Karolinska Institutet, Stockholm, Sweden

Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden

Nutrition & Metabolism 1743-7075 2007 4 1 2 http://www.nutritionandmetabolism.com/content/4/1/2 17212815 10.1186/1743-7075-4-2 29 8 2006 09 1 2007 09 1 2007 2007 Wallin et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Surgery, commonly performed after an overnight fast, causes a postoperative decline in the anabolic and glucose lowering insulin-like growth factor-1 (IGF-1). Clinical fasting studies have exhibited a positive correlation between IGF-1 and nitrogen balance during different conditions. A perioperative amino acid infusion changes nitrogen balance and might thereby influence serum IGF-1. We hypothesized that amino acid infusion would enhance IGF-1 and thereby might influence glucose homeostasis after surgery. In this study we examined two different regimes of perioperative amino acids infusion.

Methods

24 females scheduled for abdominal hysterectomy were randomized into three groups; Ringer's solution infusion throughout anesthesia (Group B), amino acid infusion throughout anesthesia (Group C) and amino acid infusion 1 hour before anesthesia and during 1.5 hrs of surgery (Group D). Six female volunteers, who were not operated, but received the same amino acids infusion after fasting, served as controls (Group A). Fasting levels of IGF-1, Insulin-like growth factor binding protein-1 (IGFBP-1), insulin and P-glucose were studied prior to, and four days following, operation. Homeostasis model assessment (HOMA) was used as an index of insulin resistance. Non-parametric statistical methods were used.

Results

During the study the Ringer-group exhibited a decrease in IGF-1 and an increase in insulin and plasma glucose after surgery. Within the other groups there were no significant alterations over time after surgery, with the exception of a postoperative decrease in IGF-1 in group D. Group C had higher IGF-1 levels compared to group B on all days. Also, group D had higher IGF-1 levels than group B on day 2 – 4. From baseline to the first postoperative day there was a significant increase in HOMA and IGFBP-1 in groups B and C. These changes were not found in group D, in which insulin, glucose, HOMA and IGFBP-1 did not change. Amino acid infusion to the volunteers did not affect any of the variables studied.

Conclusion

Amino acid infusion during surgery attenuates the decrease in IGF-1 and diminishes the "diabetes of injury".

Background

Elective surgery is traditionally performed after an overnight fast in order to reduce the risk of aspiration. It has recently been shown that preoperative carbohydrate treatment reduces insulin resistance after surgery with a shorter length of hospital stay 1. Shorter hospitalization has also been reported after amino acid treatment during surgery 2. The insulin-like growth factor-1 (IGF-1) is a common denominator for amino acid and carbohydrate metabolism 3. The anabolic axis of growth hormone (GH) and IGF-1 is sensitive to nutritional variations 45. Fasting and catabolic states cause an uncoupling between IGF-1 and GH with high serum levels of GH and low IGF-1 6. Both sufficient energy and protein intake are necessary for a normal IGF-1 response to GH. IGF-1 stimulates amino acid and glucose uptake as well as protein synthesis in muscle 37. In humans, IGF-1 also reduces B-glucose in parallel with insulin 8910. Circulating IGF-1 is produced in the liver and more than 99 % is bound to binding proteins (IGFBPs, 1–6) 411. About 80–90% is bound to a stable ternary protein complex consisting of IGF-1, IGFBP-3 and Acid Labile Subunit (ALS) with a long half-life (≈15 h)1213. The ternary complex stabilize the concentration of IGF-1 in plasma and regulates the efflux of free IGF-1 from the vascular space 14. The smaller IGFBPs (IGFBP-1, -2, -4, -6) form binary complexes with IGF-1 and do not bind to ALS. Only the free fraction, which is less than 1% of total IGF-1, is supposed to be active at the receptor11. After surgery 1516 and during pregnancy 17 and critical illness 1819 an proteolytic activity is observed which reduces the half-life of IGF-1. In addition, serum levels of the smaller binding proteins are often elevated during critical illness 20.

Insulin-like growth factor binding protein-1 (IGFBP-1), produced in the liver 1121, is an important regulator of free IGF-1. Its production is inhibited by insulin at the transcription level 22 and is stimulated by glucagon 23, epinephrine 24 and cytokines 25. IGFBP-1, free IGF-1 and insulin all of them have a half-life about 5–10 minutes 111326.

IGF-1 is also produced in other tissues, such as muscle, and acts as a paracrine and autocrine growth factor 27. This local production is also dependent on GH, and nutrition 428.

A number studies in fasting subjects have described a close correlation between total IGF-1 and nitrogen balance 428. Earlier studies have reported increased renal utilization of amino acids with increasing blood concentration 29. Thus infusion of amino acids ought to be utilized by patients during surgery. In humans amino acids act both as substrates and transmitters. The effect of an amino acid infusion during surgery might thus be different if it is given before or after induction of anesthesia. The postoperative effect of amino acid infusion given during anesthesia and surgery concerning IGF-1 and glucose homeostasis has previously not been elucidated. The aim of this pilot study was to investigate the effect of two regimes of amino acids infusion, before and during hysterectomy, on the surgery induced decrease in IGF-1 and "diabetes of injury" 30.

Methods

Thirty women were included in the study. Patients with known metabolic, hepatic or renal disorders were not included in this study and none of the studied subjects had reported any weight changes prior the investigation. Neither of them was on any drug treatment. They were all informed of the study and its risks before they consented to participate. The study protocol was approved by the Ethics Committee at Karolinska Hospital.

Study groups

The subjects were divided into four study groups. Six female volunteers acted as a control group from the normal population (group A). They were fasting over night but otherwise had no food restrictions during the study and were given an i.v. amino acid infusion for 2.5 h, in an amount that was similar to the two amino acid treated patient groups. The volunteers were not hospitalized or subjected to anesthesia or surgery. Twenty-four female patients scheduled for hysterectomy due to myoma were randomly divided into three groups (groups B, C, D). Eight control patients were anaesthetized and received no amino acids, but a corresponding volume (126 mL/h) of Ringer's solution, (group B). Another group of 8 patients received amino acid infusions starting at induction of anesthesia and continuing throughout surgery until awakening (group C). In group D, eight patients were given amino acids during 1 h before induction of anesthesia and for additional 1.5 h into anesthesia and surgery.

Anesthesia

Prior to anesthesia and surgery all patients were on an unrestricted mixed diet. The estimated intake of nitrogen and energy 24 h before the study were of the same magnitude in all groups. They were all fasted over-night and got an oral premedication of lorazepam 1 mg 1 h prior to anesthesia. Before induction of anesthesia two cubital veins were catheterized. One catheter for amino acid infusion or acetated Ringer's solution was inserted and advanced centrally 30 cm to reach a tip position in the subclavian vein. The venous catheter in the other arm was used for anesthetic drug administration. Anesthesia was induced with thiopental, 5 mg/kg, and the trachea was intubated after a bolus dose of atracurium 0.5 mg/kg followed by a continuous infusion of 0.5 mg/kg/h. Anesthesia was maintained with 1–2% of isoflurane in O₂/N₂O. Fresh gas flows were set at 2 L/min of O₂and 4 L/min of N₂O, using a partial rebreathing circuit (Dameca ventilator 109 40, Dameca, Rødøvre, Denmark). Usual monitors were used. Before the start of surgery fentanyl 3 μg/kg was given. The atracurium infusion was stopped 0.5 h before the end of the operation, and muscle relaxation was antagonized with 2.5 mg of neostigmine and 0.5 mg of glycopyrrolate at the end of surgery. Postoperatively, pain relief was standardized and given according to routine as needed.

During anesthesia and surgery, 500 mL/h of Ringer's solution was infused i.v. in all patients. After emergence from anesthesia, 1000–1500 mL of a 5 % glucose solution was administered in all patients until the next morning. The first postoperative day the patients were on a liquid diet. From the second day after surgery the patients had regular meals. All postoperative energy and nitrogen intake was daily recorded throughout the study. Energy and nitrogen intake were equal during each postoperative day in the three patient groups.

Amino acid infusion

All studies commenced at 7.30 a.m Healthy volunteers (group A) reported in the morning after an overnight fast. They received a balanced amino acid mixture (Vamin^®18 g N/L, Pharmacia, Stockholm, Sweden) at a rate of 126 mL/h, corresponding to 240 kJ of energy per h. The mixture of amino acids in Vamin^®18 g N/L is presented in Table 1. Thus, during 2.5 h of infusion, the subjects in group A received 600 kJ of extra energy from amino acids and totally 397 mmoles nitrogen was infused. The patients in group D, in which the amino acid infusion started 1 h before induction of anesthesia and continued during the first 1.5 h of anesthesia and surgery, received exactly the same amounts of energy and nitrogen, i.e. 600 kJ and 397 mmoles, respectively. The patients in group C received an identical amino acid infusion throughout anesthesia and obtained 384 ± 24 mmoles (mean ± SEM) of nitrogen. The patients' ward nurses, as well as surgeons, were unaware of whether amino acids or saline was given. Otherwise the study was not blinded.

Table 1

The content of amino acids in – Vamin^®18 – per 1000 mL.

glycine 7.9 g

histidine 6.8 g

proline 6.8 g

aspartate 3.4 g

isoleucine 5.6 g

serine 4.5 g

glutamate 5.6 g

leucine 7.9 g

threonine 5.6 g

alanine 16.0 g

lysine 9.0 g

tryptophan 1.9 g

arginine 11.3 g

methionine 5.6 g

tyrosine 230 mg

cysteine 560 mg

phenylalanine 7.9 g

valine 7.3 g.

Measurements and analyses

Blood samples were taken, after an overnight fast, in the mornings of the day of surgery and during the first four postoperative days. Blood samples were stored cold and centrifuged within 2 h. Serum was frozen at -80°C. Samples were analyzed at the same occasion after the study was completed. IGF-1, IGFBP-1, insulin and plasma-glucose were analyzed. Serum concentrations of total IGF-I were determined by RIA after acid ethanol extraction to minimize interference with IGFBPs 31. The truncated des (1–3) IGF-I that has reduced affinity for IGFBPs was used as the radioligand in the IGF-I RIA. IGFBP-1 was determined in serum by RIA as described by Povoa et al. 32.

Insulin was measured with a commercial RIA-kit, Pharmacia Insulin (Pharmacia, Stockholm, Sweden) and plasma glucose was analyzed by an enzymatic electrochemical method using a glucose analyzer (YSI, Yellow Springs, OH).

HOMA (Homeostasis model assessment) a index of insulin resistance: p-glucose × p-insulin/22.5 33.

Statistics

Non-parametric statistical methods were used for the statistical analyses since the biochemical data was not normally distributed. Mann-Whitney test was initially used for preoperative comparisons between groups. Friedmans ANOVA was used to test postoperative alterations of the variables in the groups. If the ANOVA showed significance another Mann-Whitney test was performed for each postoperative day for comparisons between groups after surgery.

Finally, Wilcoxon signed rank test was done for a comparison of preoperative baseline levels with the values the day after surgery. All statistical analyses were performed with SPSS (Chicago, Il). A p value ≤ 0.05 was considered as an indication of statistical significance.

Results

There were no significant differences between the four groups with regard to age, weight, and height (Table 2). Duration of anesthesia and surgery were also similar in the three operated patient groups (Table 2).

Table 2

Demographic data, duration of anesthesia and surgery for 24 patients and 6 volunteers without surgery.

Study Groups

Age (year)

Weight (kg)

Height (cm)

Duration of anesthesia (min)

Duration of surgery (min)

Group A

50 ± 3

63 ± 3

170 ± 2

Group B

50 ± 2

64 ± 2

165 ± 1

125 ± 8

92 ± 6

Group C

48 ± 1

68 ± 3

163 ± 2

121 ± 9

94 ± 9

Group D

48 ± 2

61 ± 1

164 ± 2

120 ± 5

87 ± 4

Demographic data, duration of anesthesia and surgery for 24 patients scheduled for hysterectomy and 6 volunteers without surgery. Group A = Amino acid infusion but no anesthesia or surgery; Group B = Ringer's solution infusion throughout anesthesia; Group C = Amino acid infusion throughout anesthesia; Group D = Amino acid infusion started 1 h before anesthesia and during 1.5 h of surgery. Values are mean ± SEM.

The value of blood analyses are displayed by groups for each single patient and variable in Figure 1, 2, 3, 4, 5. Results are also presented in Figure 6, 7, 8, 9, 10 as median, first and third quartile for each analyte and is also described in the text below. Among the operated patients, group C had a significantly lower level of IGFBP-1 before surgery than group B and D (Figure 5 &10). Regarding the other variables, there were no significant differences between the groups at baseline.

Figure 1

Fasting IGF-1 for each patient sorted by groups

Fasting IGF-1 for each patient sorted by groups.

Figure 2

Fasting insulin for each patient by sorted groups

Fasting insulin for each patient by sorted groups. Patient D5:s sample day 3 is probably not a true fasting value since it is only at this day she has increased levels of insulin and glucose.

Figure 3

Fasting P-glucose for each patient sorted by groups

Fasting P-glucose for each patient sorted by groups. Patient D5:s sample day 3 is probably not a true fasting value since it is only at this day she has increased levels of insulin and glucose.

Figure 4

HOMA for each patient sorted by groups

HOMA for each patient sorted by groups. Patient D5:s sample day 3 is probably not a true fasting value since it is only at this day she has increased levels of insulin and glucose.

Figure 5

Fasting IGFBP-1 for each patient sorted by groups

Fasting IGFBP-1 for each patient sorted by groups.

Figure 6

Median, first and third quartile for IGF-1 by groups

Median, first and third quartile for IGF-1 by groups. Patient D5s sample day 3 is withdrawn in these figure since it is considered to be a false fasting sample (figure 2 - 4). Significant alteration (p < 0.05) tested by Friedman ANOVA during the study is marked *. Postoperative significant (p < 0.05) differences in IGF-1 between group B and the amino acid groups are marked C and D respectively. Significant (p < 0.05) difference between baseline and the first postoperative day is marked #.

Figure 7

Median, first and third quartile for insulin by groups

Median, first and third quartile for insulin by groups. Patient D5s sample day 3 is withdrawn in these figure since it is considered to be a false fasting sample (figure 2 - 4). Significant alteration (p < 0.05) tested by Friedman ANOVA during the study is marked *. Significant (p < 0.05) difference between baseline and the first postoperative day is marked #.

Figure 8

Median, first and third quartile for P-glucose by groups

Median, first and third quartile for P-glucose by groups. Patient D5s sample day 3 is withdrawn in these figure since it is considered to be a false fasting sample (figure 2 - 4). Significant alteration (p < 0.05) tested by Friedman ANOVA during the study is marked *. Significant (p < 0.05) difference between baseline and the first postoperative day is marked #.

Figure 9

Median, first and third quartile for HOMA by groups

Median, first and third quartile for HOMA by groups. Patient D5s sample day 3 is withdrawn in these figure since it is considered to be a false fasting sample (figure 2 - 4). Significant (p < 0.05) difference between baseline and the first postoperative day is marked #.

Figure 10

Median, first and third quartile for IGFBP-1 by groups

Median, first and third quartile for IGFBP-1 by groups. Patient D5s sample day 3 is withdrawn in these figure since it is considered to be a false fasting sample (figure 2 - 4). Preoperative difference between group C and the other groups in IGFBP-1 is marked C. Significant (p < 0.05) difference between baseline and the first postoperative day is marked #.

During the study period Group B, the Ringer-group, exhibited a decrease in IGF-1 (from 139 to 91 μg/L; p = 0.002, Figure 1 &6) and an increase in insulin (from 6 to18 mU/L; p < 0.02, Figure 2 &7) as well plasma glucose (from 3.9 to 4.7 mmol/L; p < 0.05, Figure 3 &8) after surgery. HOMA was increased (from 0.8 to 3.7) but did not reach significance (p = 0.07, Figure 4 &9). IGFBP-1 was unchanged (Figure 5 &10). Within the other groups there were no significant alterations over time after surgery in any variable, with the exception of IGF-1 in group D which decreased postoperatively from 153 to116 μg/L (p < 0.05, Figure 1 &6). Group C had significantly higher IGF-1 levels compared to group B on all postoperative days (p < 0.05, Figure 6). Also group D had significantly higher IGF-1 levels than group B, but only on day 2 – 4 after surgery (p < 0.05, Figure 6). No significant differences in IGF-1 levels occurred between groups C and D.

From baseline to the first postoperative day there was a significant increase in group B and C in HOMA (from 0.8 to1.3 and 1.2 to1.8 respectively; p < 0.05, Figure 9) and IGFBP-1 (from 35 to45 μg/L and 16 to23 μg/L; p < 0.05, Figure 10). The increase in insulin in group B (6 to 7 mU/L; p = 0.06) and C (6 to 9 mU/L; p = 0.02) only reached significance for group C (Figure 7). Group B was the only group that had a postoperative increase in P-glucose (3.9 to 4.3 mmol/L; p < 0.05, Figure 8). These changes were not found in group D, in which insulin, glucose, HOMA and IGFBP-1 did not change significantly. IGF-1, however, decreased in both group B (139 to101 μg/L; p < 0.05) and group D (153 to132 μg/L; p < 0.05) the first postoperative day (Figure 6).

Amino acid infusion given to fasted volunteers did not affect any of the variables studied, neither on the first postoperative day nor during the study period.

Discussion

Our study shows that an amino acid infusion during surgery attenuates the surgery-induced decline in IGF-1. This effect was most pronounced in the group who received amino acids throughout anesthesia. A decrease in IGF-1 during surgery is a general phenomenon described after both abdominal, heart and hip surgery 19343536 during different types of anesthesia. In the present study surgery was performed during the same type of anesthesia so the influence of anesthetic agents would not obscure the interpretation of the intervention.

The preserved IGF-1 levels found in the present study will most probably be a clinically important finding since reduced levels of IGF-1 are linked with postoperative catabolism. Protracted postoperative catabolism is a risk factor for complications and prolonged hospitalization. Administration of high doses of GH perioperatively has shown that retained IGF-1 levels are associated with improved nitrogen balance 3738. However, GH-treatment perioperatively is unsuitable since GH-treated critically ill patients, in two large randomized studies, had doubled mortality compared to their controls 39. The mechanism behind this unexpected dramatic adverse effect by rhGH-treatment is still unknown but supposed to be caused by GHs immune modulating effect or GHs secondary negative effect on glucose homeostasis 40. IGF-1 is not suspected and in a review IGF-1 was demonstrated to be safe 41. Actually, maintained or restored IGF-1 levels have a potential to confer long term health benefits. Retained concentration of IGF-1 reduces the risk of diabetes, sarcopenia and cognitive attenuation 4241 and in elderly also the risk of ischemic heart diseases 43. Thus, to maintain IGF-1 after surgery in a cost-effective and safe manner may be beneficial.

Preserved levels of IGF-1 after surgery has previously otherwise only been reported when extremely high doses of insulin were given together with glucose and potassium (GIK) during heart surgery 35. The present study shows that it actually also is possible to influence the postoperative decrease in IGF-1 with a balanced amino acid mixture supply.

The protracted "diabetes of injury" usually seen after surgery existed in the Ringer-group but was attenuated in the amino acid groups. In particular, amino acid infusion before and during surgery totally abolished the increase in insulin, and diminished the increase in IGFBP-1 and HOMA seen in the other operated groups on the first postoperative day.

Improved glucose control during cardiac surgical procedures decreases the risk for postoperative complications 44. Furthermore, tight blood glucose control, with intensive insulin therapy, dramatically reduces mortality and morbidity in critically ill patients 30. These findings indicate that our results, that amino acids infusion improves glucose homeostasis, might be clinically important.

There are some possible explanations why amino acid infusion might attenuate the surgery induced protracted insulin resistance. First, the preserved levels of IGF-1 in the amino acid groups might contribute since increased levels of IGF-1 is shown to reduce insulin resistance 89. However, Skjaerbaek et al. found unchanged levels of free IGF-1 despite a significant decrease of total IGF-1 after surgery45. They suggest that the increased protelytic activity preserves the level of free IGF-1. Free IGF-1 was not measured in the present study so the preserved levels of IGF-1 may not completely explain the improved glucose homeostasis in the amino acid groups. Hence, other mechanisms had to be considered.

The balanced amino acid mixture used in the study contains L-Arginine, a precursor for NO. L-arginine acutely initiates the secretion of insulin, glucagon and GH. Both intravenous infusion 46, and long-term oral administration in diabetic patients 47 of L-arginine have been demonstrated to improve insulin sensitivity. The dose of L-arginine, given in our study, is compatible with the low-dose used by Wascher et al46. Hence, this effect of L-arginine might be of importance.

The greatest effect of a perioperative amino acid infusion on the short-acting IGFBP-1 and insulin was seen at the first day after surgery. On the day after surgery, the group receiving amino acid infusion before and during the first part of surgery (D) had lower levels of insulin than the patients receiving amino acids only during surgery (C). The most probable reason for this is the different regimes of amino acid administration. An infusion of amino acids in rats caused a decrease in IGFBP-1 without any changes in insulin 48. A decrease in IGFBP-1 with unchanged insulin levels is known to reflect an improved hepatic insulin sensitivity 49. Furthermore, the free glucose lowering fraction of IGF-1 depends on changes in IGFBP-1, the only binding protein demonstrated to have acute metabolic effects 50. In the amino acid-treated rats, a higher concentration of total IGF-1 was detected 48 in agreement with our findings. Our results suggest that preoperative amino acid infusion has a pharmacological effect and preserves IGFBP-1 postoperatively in traumatized individuals. Consequently, the timing of the amino acids infusion might be of importance for the metabolic response.

Our patient groups were unfortunately not perfectly matched at baseline. The lower levels of IGFBP-1 and a tendency to greater body weight in group C, may suggest an alternative explanation of the difference in insulin pattern between groups C and D. Individuals that have low IGFBP-1 before surgery (patients C₁, C₃, C₆) have also high insulin levels postoperatively, figures 1, 2, 3, 4, 5. From earlier studies it is known that obesity, low levels of IGFBP-1 and an increased IGF-1:IGFBP-1 ratio are factors associated with insulin resistance in men and women 4951. This possibly altered basal metabolism in some of the individuals in group C might be an additional reason for the different metabolic pattern between the two treatment groups.

In the Ringer-group we found a pathological metabolic pattern after operation, with depressed IGF-1 and protracted increased levels of glucose and insulin. In both treatment groups, amino acid infusion attenuated the surgery related decline in IGF-1, and improved glucose homeostasis. However, in none of the amino acid groups the amino acid regime were optimized. The optimal dose and timing of perioperative amino acid therapy need to be clarified in larger studies. The amino acid infusion could probably start well ahead of anaesthesia and continue during surgery. At least 60 minutes prior to anaesthesia seems to be appropriate. A possible advantage of a continued infusion after operation has also to be investigated. The exact mechanism behind this favourable effect has also to be elucidated in further studies.

Conclusion

Our study shows that amino acid infusion during surgery reduces the decrease in IGF-1. It also indicates that amino acid therapy before and during surgery diminishes "diabetes of injury". Larger studies are required to find out doses, timing and mechanisms behind the favourable effects of amino acid therapy during surgery.

Our findings might change the perioperative infusion therapy in the future.

Abbreviations

IGF-1 = Insulin-like growth factor-1

GH = Growth hormone

IGFBP-1 = Insulin-like growth factor binding protein-1

HOMA = Homeostasis model assessment

RIA = Radioimmuno assay

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

MW and ES conceived the study; MW drafted the manuscript; ES was responsible for the clinical data collection and helped to draft the manuscript; SE acted as a statistical consultant and made the figures; KB was responsible for the laboratory analysis, helped to draft the manuscript and rose the funding that made the study possible. All authors have substantially contributed to the manuscript and approved the final manuscript.

Acknowledgements

This study was supported by grants from the Family Persson Foundation and Swedish Medical Research Council 04224.

Preoperative oral carbohydrate nutrition: an update Nygren J Thorell A Ljungqvist O Curr Opin Clin Nutr Metab Care 2001 4 255 259 10.1097/00075197-200107000-00002 11458017 Amino acid-induced thermogenesis reduces hypothermia during anesthesia and shortens hospital stay Sellden E Lindahl SG Anesth Analg 1999 89 1551 1556 10.1097/00000539-199912000-00045 10589647 Insulin-like growth factor I exerts growth hormone- and insulin-like actions on human muscle protein metabolism Fryburg DA Am J Physiol 1994 267 E331 6 8074213 Nutritional regulation of IGF-I and IGF binding proteins Clemmons DR Underwood LE Annu Rev Nutr 1991 11 393 412 10.1146/annurev.nu.11.070191.002141 1716449 Nutritional regulation of the insulin-like growth factors Thissen JP Ketelslegers JM Underwood LE Endocr Rev 1994 15 80 101 10.1210/er.15.1.80 8156941 Fasting affects serum insulin-like growth factors (IGFs) and IGF-binding proteins differently in patients with noninsulin-dependent diabetes mellitus versus healthy nonobese and obese subjects Bang P Brismar K Rosenfeld RG Hall K J Clin Endocrinol Metab 1994 78 960 967 10.1210/jc.78.4.960 7512573 Use of a leucine clamp to demonstrate that IGF-I actively stimulates protein synthesis in normal humans Russell-Jones DL Umpleby AM Hennessy TR Bowes SB Shojaee-Moradie F Hopkins KD Jackson NC Kelly JM Jones RH Sonksen PH Am J Physiol 1994 267 E591 8 7943309 Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose Clemmons DR Moses AC Sommer A Jacobson W Rogol AD Sleevi MR Allan G Growth Horm IGF Res 2005 15 265 274 10.1016/j.ghir.2005.05.002 16005252 The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity Clemmons DR Moses AC McKay MJ Sommer A Rosen DM Ruckle J J Clin Endocrinol Metab 2000 85 1518 1524 10.1210/jc.85.4.1518 10770191 Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion Zenobi PD Graf S Ursprung H Froesch ER J Clin Invest 1992 89 1908 1913 295890 1601998 Development and clinical evaluation of a novel immunoassay for the binary complex of IGF-I and IGF-binding protein-1 in human serum Frystyk J Hojlund K Rasmussen KN Jorgensen SP Wildner-Christensen M Orskov H J Clin Endocrinol Metab 2002 87 260 266 10.1210/jc.87.1.260 11788656 High molecular weight insulin-like growth factor binding protein complex. Purification and properties of the acid-labile subunit from human serum Baxter RC Martin JL Beniac VA J Biol Chem 1989 264 11843 11848 2473065 Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects Guler HP Schmid C Zapf J Froesch ER Proc Natl Acad Sci U S A 1989 86 2868 2872 287020 2649897 10.1073/pnas.86.8.2868 Impaired blockade of insulin-like growth factor I (IGF-I)-induced hypoglycemia by IGF binding protein-3 analog with reduced ternary complex-forming ability Firth SM McDougall F McLachlan AJ Baxter RC Endocrinology 2002 143 1669 1676 10.1210/en.143.5.1669 11956148 Insulin-like growth factor-binding protein-3 proteolysis is induced after elective surgery Davenport ML Isley WL Pucilowska JB Pemberton LB Lyman B Underwood LE Clemmons DR J Clin Endocrinol Metab 1992 75 590 595 10.1210/jc.75.2.590 1379257 Postoperative induction of insulin-like growth factor binding protein-3 proteolytic activity: relation to insulin and insulin sensitivity Bang P Nygren J Carlsson-Skwirut C Thorell A Ljungqvist O J Clin Endocrinol Metab 1998 83 2509 2515 10.1210/jc.83.7.2509 9661636 Insulin-like growth factor binding protein-3 is functionally altered in pregnancy plasma Lassarre C Binoux M Endocrinology 1994 134 1254 1262 10.1210/en.134.3.1254 7509737 The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness Davies SC Wass JA Ross RJ Cotterill AM Buchanan CR Coulson VJ Holly JM J Endocrinol 1991 130 469 473 1719118 The differential regulation of the circulating levels of the insulin-like growth factors and their binding proteins (IGFBP) 1, 2 and 3 after elective abdominal surgery Cotterill AM Mendel P Holly JM Timmins AG Camacho-Hubner C Hughes SC Ross RM Blum WF Langford RM Clin Endocrinol (Oxf) 1996 44 91 101 10.1046/j.1365-2265.1996.649471.x 8706300 Role of growth hormone, insulin-like growth factor-I, and insulin-like growth factor binding proteins in the catabolic response to injury and infection Lang CH Frost RA Curr Opin Clin Nutr Metab Care 2002 5 271 279 10.1097/00075197-200205000-00006 11953652 Insulin-like growth factor (IGF) binding proteins: the role of serum IGFBPs in regulating IGF availability Baxter RC Acta Paediatr Scand Suppl 1991 372 107 114 1718141 Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes Brismar K Fernqvist-Forbes E Wahren J Hall K J Clin Endocrinol Metab 1994 79 872 878 10.1210/jc.79.3.872 7521354 Glucagon stimulates insulin-like growth factor binding protein-1 secretion in healthy subjects, patients with pituitary insufficiency, and patients with insulin-dependent diabetes mellitus Hilding A Brismar K Thoren M Hall K J Clin Endocrinol Metab 1993 77 1142 1147 10.1210/jc.77.5.1142 7521339 Influence of circulating epinephrine and norepinephrine on insulin-like growth factor binding protein-1 in humans Fernqvist-Forbes E Hilding A Ekberg K Brismar K J Clin Endocrinol Metab 1997 82 2677 2680 10.1210/jc.82.8.2677 9253353 Regulation of IGF binding protein-1 in hep G2 cells by cytokines and reactive oxygen species Lang CH Nystrom GJ Frost RA Am J Physiol 1999 276 G719 27 10070049 Effect of human insulin-like growth factor-binding protein-1 on the half-life and action of administered insulin-like growth factor-I in rats Lewitt MS Saunders H Cooney GJ Baxter RC J Endocrinol 1993 136 253 260 7681466 Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action D'Ercole AJ Stiles AD Underwood LE Proc Natl Acad Sci U S A 1984 81 935 939 344954 6583688 10.1073/pnas.81.3.935 Nutritional regulation of insulin-like growth factor-I Ketelslegers JM Maiter D Maes M Underwood LE Thissen JP Metabolism 1995 44 50 57 10.1016/0026-0495(95)90221-X 7476312 Renal oxygen consumption, thermogenesis, and amino acid utilization during i.v. infusion of amino acids in man Brundin T Wahren J Am J Physiol 1994 267 E648 55 7977714 How does blood glucose control with insulin save lives in intensive care? Van den Berghe G J Clin Invest 2004 114 1187 1195 524243 15520847 10.1172/JCI200423506 Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand Bang P Eriksson U Sara V Wivall IL Hall K Acta Endocrinol (Copenh) 1991 124 620 629 2068892 Isolation and characterization of a somatomedin-binding protein from mid-term human amniotic fluid Povoa G Enberg G Jornvall H Hall K Eur J Biochem 1984 144 199 204 10.1111/j.1432-1033.1984.tb08449.x 6208022 Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Matthews DR Hosker JP Rudenski AS Naylor BA Treacher DF Turner RC Diabetologia 1985 28 412 419 10.1007/BF00280883 3899825 Perioperative insulin and glucose infusion maintains normal insulin sensitivity after surgery Nygren JO Thorell A Soop M Efendic S Brismar K Karpe F Nair KS Ljungqvist O Am J Physiol 1998 275 E140 8 9688885 The influence of glucose-insulin-potassium (GIK) on the GH/IGF-1/IGFBP-1 axis during elective coronary artery bypass surgery Wallin M Barr G Owall A Lindahl SG Brismar K J Cardiothorac Vasc Anesth 2003 17 470 477 10.1016/S1053-0770(03)00152-6 12968235 Repeated administration of recombinant human insulin-like growth factor-I in patients after gastric surgery. Effect on metabolic and hormonal patterns Goeters C Mertes N Tacke J Bolder U Kuhmann M Lawin P Lohlein D Ann Surg 1995 222 646 653 1234992 7487212 10.1097/00000658-199511000-00007 Biosynthetic human growth hormone preserves both muscle protein synthesis and the decrease in muscle-free glutamine, and improves whole-body nitrogen economy after operation Hammarqvist F Stromberg C von der Decken A Vinnars E Wernerman J Ann Surg 1992 216 184 191 1242590 1503519 10.1097/00000658-199208000-00009 Growth hormone treatment prevents the decrease in insulin-like growth factor I gene expression in patients undergoing abdominal surgery Bjarnason R Wickelgren R Hermansson M Hammarqvist F Carlsson B Carlsson LM J Clin Endocrinol Metab 1998 83 1566 1572 10.1210/jc.83.5.1566 9589657 Increased mortality associated with growth hormone treatment in critically ill adults Takala J Ruokonen E Webster NR Nielsen MS Zandstra DF Vundelinckx G Hinds CJ N Engl J Med 1999 341 785 792 10.1056/NEJM199909093411102 10477776 Treatment with GH and IGF-1 in critical illness Teng Chung T Hinds CJ Crit Care Clin 2006 22 29 40 10.1016/j.ccc.2005.09.003 16399018 Recombinant human insulin-like growth factor I (IGF-I): risks and benefits of normalizing blood IGF-I concentrations Clark RG Horm Res 2004 62 Suppl 1 93 100 10.1159/000080766 15761240 Clinical implications of the reduced activity of the GH-IGF-I axis in older men Ceda GP Dall'Aglio E Maggio M Lauretani F Bandinelli S Falzoi C Grimaldi W Ceresini G Corradi F Ferrucci L Valenti G Hoffman AR J Endocrinol Invest 2005 28 96 100 16760634 The Prospective Association of Serum Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-1 Levels with All Cause and Cardiovascular Disease Mortality in Older Adults: The Rancho Bernardo Study Laughlin GA Barrett-Connor E Criqui MH Kritz-Silverstein D J Clin Endocrinol Metab 2004 89 114 120 10.1210/jc.2003-030967 14715837 Outcomes and perioperative hyperglycemia in patients with or without diabetes mellitus undergoing coronary artery bypass grafting Estrada CA Young JA Nifong LW Chitwood WR Jr. Ann Thorac Surg 2003 75 1392 1399 10.1016/S0003-4975(02)04997-4 12735552 Differential changes in free and total insulin-like growth factor I after major, elective abdominal surgery: the possible role of insulin-like growth factor-binding protein-3 proteolysis Skjaerbaek C Frystyk J Orskov H Kissmeyer-Nielsen P Jensen MB Laurberg S Moller N Flyvbjerg A J Clin Endocrinol Metab 1998 83 2445 2449 10.1210/jc.83.7.2445 9661626 Effects of low-dose L-arginine on insulin-mediated vasodilatation and insulin sensitivity Wascher TC Graier WF Dittrich P Hussain MA Bahadori B Wallner S Toplak H Eur J Clin Invest 1997 27 690 695 10.1046/j.1365-2362.1997.1730718.x 9279534 Long-term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients Piatti PM Monti LD Valsecchi G Magni F Setola E Marchesi F Galli-Kienle M Pozza G Alberti KG Diabetes Care 2001 24 875 880 11347747 Parenteral amino acid intake alters the anabolic actions of insulin-like growth factor I in rats Kee AJ Baxter RC Carlsson AR Smith RC Am J Physiol 1999 277 E63 72 10409129 Metabolic, anthropometric, and nutritional factors as predictors of circulating insulin-like growth factor binding protein-1 levels in middle-aged and elderly men Wolk K Larsson SC Vessby B Wolk A Brismar K J Clin Endocrinol Metab 2004 89 1879 1884 10.1210/jc.2003-031349 15070959 Insulin-like growth factor-binding protein-1 modulates blood glucose levels Lewitt MS Denyer GS Cooney GJ Baxter RC Endocrinology 1991 129 2254 2256 1717244 Association between insulin-like growth factor-I: insulin-like growth factor-binding protein-1 ratio and metabolic and anthropometric factors in men and women Sandhu MS Gibson JM Heald AH Dunger DB Wareham NJ Cancer Epidemiol Biomarkers Prev 2004 13 166 170 10.1158/1055-9965.EPI-130-3 14744751